First FDA IND Approval Using Only Human Vascularized Organoids (2025) (qureator.com)

Qureator Inc. achieved a groundbreaking milestone by securing the first FDA Investigational New Drug (IND) approval using human vascularized organoids, marking a significant shift in drug development. This advancement, facilitated by their innovative AI-driven vTIME (vascularized tumor immune microenvironment) organ-on-a-chip platform, eliminates the need for traditional animal efficacy studies. The approval, granted to Qureator's partner SillaJen for its combination therapy BAL0891, underscores the potential of human-relevant testing in oncology. This development is noteworthy for the AI and ML community as it illustrates the increasing integration of advanced technologies in regulatory processes and drug development. The ability to replace animal studies with predictive human-based models not only accelerates the path to clinical application but also enhances the reliability of preclinical data. This milestone highlights a critical evolution in regulatory practices, emphasizing a collaborative approach between innovators and regulators, and positions Qureator as a leader in the next generation of preclinical research methodologies.